Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study

Overview of attention for article published in Neuropsychiatric Disease and Treatment, April 2018

Altmetric Badge

Mentioned by

facebook: 1 Facebook page

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 34 Mendeley

Summary Facebook Dimensions citations

So far, Dimensions has found 5 publications that cite this research output.

5

The most recent citing publications are shown below. View all 5 publications that cite this research output on Dimensions.

Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review

Article in BMC Psychiatry (January 2024)

Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review

Article in Neuropsychiatric Disease and Treatment (September 2023)

Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis

Article in CNS Drugs (July 2023)